Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease.
Reversible catechol-O-methyl transferase (COMT) inhibitor, Nitrocatechols
Adjunct to co-beneldopa or co-careldopa in Parkinson’s disease with ’end-of-dose’ motor fluctuations (under expert supervision) BY MOUTH Adult: 200 mg, dose to be given with each dose of levodopa with dopa-decarboxylase inhibitor; maximum 2 g per day
History of neuroleptic malignant syndrome . history of non-traumatic rhabdomyolysis . phaeochromocytoma Concurrent levodopa dose may need to be reduced by about 10?30%. ischaemic heart disease
Common or very common Abdominal pain . abnormal dreams . confusion . constipation . diarrhoea . dizziness . dry mouth . dyskinesia . dystonia . fatigue . hallucinations . insomnia . ischaemic heart disease . nausea . sweating . urine may be coloured reddish-brown . vomiting Uncommon Myocardial infarction Rare Rash Very rare Agitation . anorexia . urticaria . weight loss Frequency not known Colitis . hepatitis . neuroleptic malignant syndrome . rhabdomyolysis . skin, hair, and nail discoloration
PREGNANCY Avoid?no information available. BREAST FEEDING Avoid?present in milk in animal studies.
.png&w=384&q=75)